Schnell Pharm targets W20 bill. sales

Published: 2008-05-27 06:53:00

Updated: 2008-05-27 06:53:00

Boosted by its active merger with Genexel-Sein and intensive Research and development strategy, Schnell Pharm has set an ambitious goal of 20 billion won in sales next year.

“We will inject money and energy to develop the company's protein medicines and generic antibodies,'' a Schnell spokesma...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK